Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
Author :
Publisher : CRC Press
Total Pages : 212
Release :
ISBN-10 : 9781000590203
ISBN-13 : 1000590208
Rating : 4/5 (208 Downloads)

Book Synopsis Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials by : Andrew P. Grieve

Download or read book Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials written by Andrew P. Grieve and published by CRC Press. This book was released on 2022-06-19 with total page 212 pages. Available in PDF, EPUB and Kindle. Book excerpt: Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials provides a practical introduction to unconditional approaches to planning randomised clinical trials, particularly aimed at drug development in the pharmaceutical industry. This book is aimed at providing guidance to practitioners in using average power, assurance and related concepts. This book brings together recent research and sets them in a consistent framework and provides a fresh insight into how such methods can be used. Features: A focus on normal theory linking average power, expected power, predictive power, assurance, conditional Bayesian power and Bayesian power. Extensions of the concepts to binomial, and time-to-event outcomes and non-inferiority trials An investigation into the upper bound on average power, assurance and Bayesian power based on the prior probability of a positive treatment effect Application of assurance to a series of trials in a development program and an introduction of the assurance of an individual trial conditional on the positive outcome of an earlier trial in the program, or to the successful outcome of an interim analysis Prior distribution of power and sample size Extension of the basic approach to proof-of-concept trials with dual success criteria Investigation of the connection between conditional and predictive power at an interim analysis and power and assurance Introduction of the idea of surety in sample sizing of clinical trials based on the width of the confidence intervals for the treatment effect, and an unconditional version.


Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials Related Books

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
Language: en
Pages: 212
Authors: Andrew P. Grieve
Categories: Mathematics
Type: BOOK - Published: 2022-06-19 - Publisher: CRC Press

DOWNLOAD EBOOK

Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials provides a practical introduction to unconditional approaches to planning rando
Case Studies in Bayesian Methods for Biopharmaceutical CMC
Language: en
Pages: 354
Authors: Paul Faya
Categories: Mathematics
Type: BOOK - Published: 2022-12-15 - Publisher: CRC Press

DOWNLOAD EBOOK

The subject of this book is applied Bayesian methods for chemistry, manufacturing, and control (CMC) studies in the biopharmaceutical industry. The book has mul
Bayesian Adaptive Methods for Clinical Trials
Language: en
Pages: 316
Authors: Scott M. Berry
Categories: Mathematics
Type: BOOK - Published: 2010-07-19 - Publisher: CRC Press

DOWNLOAD EBOOK

Already popular in the analysis of medical device trials, adaptive Bayesian designs are increasingly being used in drug development for a wide variety of diseas
Case Studies in Innovative Clinical Trials
Language: en
Pages: 303
Authors: Kristine Broglio
Categories: Mathematics
Type: BOOK - Published: 2023-11-27 - Publisher: CRC Press

DOWNLOAD EBOOK

Drug development is a strictly regulated area. As such, marketing approval of a new drug depends heavily, if not exclusively, on evidence generated from clinica
Model-Assisted Bayesian Designs for Dose Finding and Optimization
Language: en
Pages: 234
Authors: Ying Yuan
Categories: Medical
Type: BOOK - Published: 2022-11-11 - Publisher: CRC Press

DOWNLOAD EBOOK

Bayesian adaptive designs provide a critical approach to improve the efficiency and success of drug development that has been embraced by the US Food and Drug A